Figure 2 Immunohistochemical staining of ERCC1 proteins in NLCLC tissues. Expression of ERCC1 protein was detected in the nuclei of cancer cells. a-f: squamous carcinoma; g-l: adenocarcinoma. Correlation between ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 expression and clinical features The expression of five genes in different clinical features were compared and summarized. It showed that the difference of these five genes were only significant between some parts of clinical features. Correlations were observed between ERCC1 expression and TNM stage (P = 0.006), metastasis of lymph node (P
= 0.01), and TUBB3 expression and TNM stage (P = 0.004). No Correlation was observed between ERCC1, TUBB3 expression and other clinical features. Besides, No Correlation was observed between BAG-1, BRCA1, RRM1 check details expression and gender, age, nationality, histology, differentiation of tumor, metastasis of lymph node, TNM stage, chemotherapy status or performance status. Association between gene expression and survival after surgical resection The CA4P median follow-up time was 23.3 months (range 2.3-42.6), and the median overall survival and median PFS (progression-free survival) were 27.2 months (range 2.3-42.6) and 26.5 months (range 0.8-42.6), respectively. Figures 3, 4, 5 and 6 showed the Kaplan-Meier survival curves in patients positive and negative for ERCC1 and BAG-1 expression. Patients negative for ERCC1 expression had a significantly longer median progression-free
(more than 42.6 vs. 15.4 months. P = 0.001) and overall (more than 42.6 vs. 20.9 months. P = 0.001) survival, compared with those positive for ERCC1 expression. Patients negative for BAG-1 expression had a significantly longer median progression-free survival (more than 42.6 17-DMAG (Alvespimycin) HCl vs. 12.9 months. P = 0.001) and overall survival (more than 42.6 vs. 17.0 months. P = 0.001), than those positive for BAG-1 expression. The relationships between the PFS and BRCA1, RRM1 and TUBB3 were no statistical
significance (P = 0.088, P = 0.116 and P = 0.271), and there were also the same results for OS (P = 0.057, P = 0.110 and P = 0.342). Figure 3 Progression-free survival according to ERCC1 expression (more than 42.6 vs. 15.4 months, P = 0.001). Figure 4 Overall survival according to ERCC1 expression (more than 42.6 vs. 20.9 months, P = 0.001). Figure 5 Progression-free survival according to BAG-1 expression (more than 42.6 vs. 12.9 months, P = 0.001). Figure 6 Overall survival according to BAG-1 expression (more than 42.6 vs. 17.0 months, P = 0.001). Median value of clinicopathologic selleck screening library factors and expression of genes of tumor samples were used as a cut-off point at univariate analysis. Univariate Cox analysis was carried out to identify the factors that were significantly associated with progression-free and overall survival (Table 3). In the univariate analysis, ERCC1 expression (P = 0.001), BAG-1 expression (P = 0.001), TNM stage (P = 0.007) and metastasis of lymph node (P = 0.